44例儿童神经母细胞瘤临床分析

朱呈光; 贺湘玲; 汤止戈; 陈可可; 邹润英; 田鑫; 游亚兰

doi:10.7499/j.issn.1008-8830.2005053

PDF(1206 KB)

HTML

中国当代儿科杂志 ›› 2020, Vol. 22 ›› Issue (11) : 1193-1197. DOI: 10.7499/j.issn.1008-8830.2005053

论著·临床研究

44例儿童神经母细胞瘤临床分析

朱呈光, 贺湘玲, 汤止戈, 陈可可, 邹润英, 田鑫, 游亚兰

作者信息 +

Clinical features of neuroblastoma: an analysis of 44 children

ZHU Cheng-Guang, HE Xiang-Ling, TANG Zhi-Ge, CHEN Ke-Ke, ZOU Run-Ying, TIAN Xin, YOU Ya-Lan

Author information +

文章历史 +

摘要

目的分析儿童神经母细胞瘤（NB）的临床特点及影响生存率的因素，为进一步优化儿童NB诊治方案提供依据。方法以2016年4月至2020年2月收治的44例NB患儿为研究对象，回顾性分析患儿的临床资料及随访资料。结果 44例NB患儿初次就诊常见临床症状依次为发热（10/44，23%）、发现肿块（9/44，20%）、腹痛（8/44，18%）、咳嗽（7/44，16%）、面色苍白（3/44，7%）、跛行（2/44，5%）及活动异常（2/44，5%）。根据INSS分期，Ⅰ期2例（4%）、Ⅱ期5例（11%）、Ⅲ期5例（11%）、Ⅳ期32例（73%）。44例患儿平均随访时间为（15.3±1.5）个月，复发率为20%，总生存率为82%，其中无事件生存29例（66%），带瘤生存7例（16%）。病理类型为NB、血清神经元特异性烯醇化酶增高可降低NB患儿的总生存率（P < 0.05）。结论 NB患儿初诊临床症状无明显特异性，多以发热、腹痛、发现肿块最常见；初诊晚期患儿占比高；病理分型为NB、血清神经元特异性烯醇化酶增高可能与NB患儿总生存率降低有关。

Abstract

Objective To study the clinical features of neuroblastoma (NB) and the factors influencing survival rate. Methods A total of 44 children with NB who were admitted from April 2016 to February 2020 were enrolled as research subjects. A retrospective analysis was performed on their medical data and follow-up data. Results The common clinical symptoms of these 44 children were fever (10/44, 23%), mass (9/44, 20%), abdominal pain (8/44, 18%), cough (7/44, 16%), pale complexion (3/44, 7%), claudication (2/44, 5%), and abnormal activity (2/44, 5%). According to the INSS stage, 2 children (4%) had stage I NB, 5 children (11%) had stage II NB, 5 children (11%) had stage III NB, and 32 children (73%) had stage IV NB. The mean follow-up time was (15.3±1.5) months, with a recurrence rate of 20% and an overall survival rate of 82%. Among the 44 children, 29 (66%) achieved event-free survival and 7 (16%) had survival with tumor. The univariate analysis showed that a pathological type of NB and an increase in serum neuron-specific enolase (NSE) decreased the overall survival rate of children with NB (P < 0.05). Conclusions The clinical symptoms of children with NB are not specific at the first visit. Fever, abdominal pain, and mass are common symptoms, and there is a high proportion of children in the advanced stage. The pathological type of NB and an increase in serum NSE may be associated with a reduction in the overall survival rate of children with NB.

导出引用

朱呈光, 贺湘玲, 汤止戈, 陈可可, 邹润英, 田鑫, 游亚兰. 44例儿童神经母细胞瘤临床分析[J]. 中国当代儿科杂志. 2020, 22(11): 1193-1197 https://doi.org/10.7499/j.issn.1008-8830.2005053

ZHU Cheng-Guang, HE Xiang-Ling, TANG Zhi-Ge, CHEN Ke-Ke, ZOU Run-Ying, TIAN Xin, YOU Ya-Lan. Clinical features of neuroblastoma: an analysis of 44 children[J]. Chinese Journal of Contemporary Pediatrics. 2020, 22(11): 1193-1197 https://doi.org/10.7499/j.issn.1008-8830.2005053

参考文献

[1] Schulte JH, Schulte S, Heukamp LC, et al. Targeted therapy for neuroblastoma:ALK inhibitors[J]. Klin Padiatr, 2013, 225(6):303-308.
[2] 中国抗癌协会小儿肿瘤专业委员会, 中华医学会小儿外科学分会肿瘤外科学组. 儿童神经母细胞瘤诊疗专家共识[J]. 中华小儿外科杂志, 2015, 36(1):3-7.
[3] Kandula S, Prabhu RS, Nanda R, et al. Outcomes after radiation therapy to metastatic sites in patients with stage 4 neuroblastoma[J]. J Pediatr Hematol Oncol, 2015, 37(3):175-180.
[4] Liang J, Tong P, Zhao W, et al. The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage[J]. Int J Mol Sci, 2014, 15(7):11220-11233.
[5] Castel V, García-Miguel P, Cañete A, et al. Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting[J]. Eur J Cancer, 1999, 35(4):606-611.
[6] Kretschmar CS, Kletzel M, Murray K, et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window:a pediatric oncology group study[J]. J Clin Oncol, 2004, 22(20):4119-4126.
[7] Howlader N, Noone AM, Yu M, et al. Use of imputed population-based cancer registry data as a method of accounting for missing information:application to estrogen receptor status for breast cancer[J]. Am J Epidemiol, 2012, 176(4):347-356.
[8] 陈吉, 黄磊, 易军. 神经母细胞瘤分子治疗研究进展[J]. 中华小儿外科杂志, 2018, 39(5):397-400.
[9] Park JR, Bagatell R, London WB, et al. Children's Oncology Group's 2013 blueprint for research:neuroblastoma[J]. Pediatr Blood Cancer, 2013, 60(6):985-993.
[10] Suita S, Tajiri T, Sera Y, et al. The characteristics of mediastinal neuroblastoma[J]. Eur J Pediatr Surg, 2000, 10(6):353-359.
[11] Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in stage 3 neuroblastoma:a report from the International Neuroblastoma Risk Group project[J]. Pediatr Blood Cancer, 2014, 61(11):1932-1939.
[12] 肖慧, 郭霞, 万智, 等. 儿童神经母细胞性肿瘤的临床特征及预后分析的单中心研究[J]. 国际输血及血液学杂志, 2017, 40(5):378-386.
[13] 孙青, 华瑛, 谢瑶, 等. 儿童神经母细胞瘤综合治疗疗效分析[J]. 中国小儿血液与肿瘤杂志, 2015, 20(5):251-255.
[14] 汤静燕, 李志光. 儿童肿瘤诊断治疗学[M]. 北京:人民军医出版社, 2011:353.
[15] 李忠元, 赵强, 王景福, 等. 100例神经母细胞瘤临床预后分析[J]. 中国肿瘤临床, 2011, 38(3):155-158.
[16] Iehara T, Hosoi H, Akazawa K, et al. MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening[J]. Br J Cancer, 2006, 94(10):1510-1515.
[17] 苏雁, 岳志霞, 金眉, 等. 单中心116例婴幼儿神经母细胞瘤临床特征及预后分析[J]. 中国小儿血液与肿瘤杂志, 2019, 24(1):19-26.
[18] Smith V, Foster J. High-risk neuroblastoma treatment review[J]. Children (Basel), 2018, 5(9):114.
[19] Gains J, Mandeville H, Cork N, et al. Ten challenges in the management of neuroblastoma[J]. Future Oncol, 2012, 8(7):839-858.